A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom

Sponsor
Bristol-Myers Squibb
Study ID
NCT04936399
Status
Completed

Conditions

  • Esophageal Squamous Cell Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — BIOLOGICAL
    Participants will receive Nivolumab after prior chemotherapy as part of an early access to medicines scheme (EAMS) program in the United Kingdom (UK)

Study Details

This purpose of this observational study is to review medical chart and patient survey data collection within an early access to medicines scheme (EAMS) program. Participant who are eligible, provide consent and enroll into the squamous cell oesophageal cancer EAMS to receive Nivolumab will be included in this study.

Key Dates

Start date
Jun 25, 2020
Status verified
May 2022
Primary completion
Dec 3, 2021
Completion
Dec 3, 2021

Study Design

Enrollment
87 participants (actual)

Arms

  • Arm: Cohort 1
    Participants with Squamous Cell Oesophageal Carcinoma Receiving Nivolumab

Primary Outcome Measure

Distribution of demographic characteristics of NSCLC participants treated with nivolumab at initiation of nivolumab treatment: Age [ Time Frame: At baseline ]

Related Studies